Particle engineering company Crystec has announced a new partnership with SignalRx Pharmaceuticals for development of an inhaled dry powder formulation of SignalRx’s SF2523 PI3K-BRD4 inhibitor for the treatment of pulmonary fibrosis, lung cancer, and COVID-19. The project is supported by Swiss life sciences investment company ADYA Consulting. According to the announcement, “Combined inhibition of both the PI3K and BRD4 pathways maximizes cellular effects in tumor and fibrosis models, and enables higher dosing with greatly improved tolerability.”
Crystec says that its mSAS supercritical anti-solvent particle engineering platform typically produces particles suitable for deposition deep in the lung. In November 2019, the company announced a deal with Swedish DPI developer Iconovo for development of mSAS particles for delivery via an Iconovo inhaler.
SignalRx CEO Matt Williams said, “We are excited to combine the unique therapeutic potential of SF2523 with the cutting-edge inhaled delivery capabilities of Crystec. With support from ADYA, we hope to bring to the market a genuinely transformative drug for the treatment of lung cancer, fibrosis, as well as COVID-19 infection and its longer-term complications.”
Read the Crystec press release.
